Verona Pharma plc - American Depositary Shares (VRNA)
VRNA moved a median of -0.03% 30 minutes after news, and -0.06% by the close. How VRNA actually reacts to news — the realized, point-in-time move the market made, measured across 325 labeled events over the last three years with zero look-ahead.
VRNA’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.03% | 45% | 296 |
| 30-min | -0.03% | 39% | 296 |
| 60-min | +0.02% | 51% | 296 |
| to close | -0.06% | 44% | 293 |
| Middle 50% of VRNA reactions | -0.80% to +0.22% |
|---|---|
| Median reaction (30-min) | -0.03% |
| Measured reactions | 325 |
Half of all Verona Pharma plc - American Depositary Shares news events land between -0.80% and +0.22% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How VRNA reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst downgrades | 21 | +0.01% | 67% | +0.01% |
| Coverage initiations | 14 | -0.50% | 43% | -0.13% |
| Rating reiterations | 51 | +0.06% | 55% | +0.09% |
| Price-target raises | 19 | +0.38% | 63% | +0.45% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how VRNA ranks against every other measured name →
That’s how VRNA usually reacts — get an email when it moves on news →Email me when VRNA moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to VRNA's baseline. Nothing else.
Recent VRNA events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 15-12G Verona Pharma plc | SEC filing · Form 15-12G | SEC EDGAR | — | — | |
| BioSpace Announces Inaugural 40 Under 40 Winners | Press release | PR Newswire | — | — | |
| Form 8-K Verona Pharma plc For: Oct 07 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form POS AM Verona Pharma plc | SEC filing · Form POS | SEC EDGAR | — | — | |
| Form POSASR Verona Pharma plc | SEC filing · Form POSASR | SEC EDGAR | — | — | |
| Form S-8 POS Verona Pharma plc | SEC filing · Form S-8 | SEC EDGAR | — | — | |
| Acquisition of Verona by MSD Approved by the High Court of Justice of England and Wales | Press release | GlobeNewswire | — | — | |
| Form 8-K Verona Pharma plc For: Sep 24 | SEC filing · Form 8-K | SEC EDGAR | -0.05% | -0.06% | |
| Shareholders of Verona Pharma Approve Proposed Acquisition by Merck | Press release | GlobeNewswire | -0.05% | -0.06% | |
| Verona Pharma to Present Additional Analyses of the Phase 3 ENHANCE Studies in COPD at ERS International Congress 2025 | Press release | GlobeNewswire | +0.00% | -0.09% | |
| Form DEFA14A Verona Pharma plc | SEC filing · Form DEFA14A | SEC EDGAR | -0.02% | +0.07% | |
| Form 8-K Verona Pharma plc For: Sep 05 | SEC filing · Form 8-K | SEC EDGAR | -0.13% | -0.05% | |
| Form DEFA14A Verona Pharma plc | SEC filing · Form DEFA14A | SEC EDGAR | -0.13% | -0.05% | |
| Melodia Therapeutics Appoints Jonathan Talbot as CEO, Sven Zimmermann as Chairman of the Board and Brings Renowned Scientific and Clinical Advisors to Propel Lead Program MLD-151 Towards the Clinic | Press release | PR Newswire | +0.07% | +0.33% | |
| TRAILBLAZERS TAKE THE STAGE: PM360 TO CROWN LIFE SCIENCES' BRIGHTEST, SEPTEMBER 30 | Press release | PR Newswire | +0.19% | — | |
| Form DEFM14A Verona Pharma plc | SEC filing · Form DEFM14A | SEC EDGAR | +0.14% | +0.47% | |
| TSLP Inhibitors Market Set for Significant Growth During the Forecast Period (2025-2034) Driven by Breakthrough Therapies | DelveInsight | Press release | PR Newswire | +0.19% | — | |
| Form 10-Q Verona Pharma plc For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.04% | +0.07% | |
| Form PREM14A Verona Pharma plc For: Aug 05 | SEC filing · Form PREM14A | SEC EDGAR | -0.04% | -0.03% | |
| Form DEFA14A Verona Pharma plc | SEC filing · Form DEFA14A | SEC EDGAR | +0.07% | -0.06% | |
| Form DEFA14A Verona Pharma plc | SEC filing · Form DEFA14A | SEC EDGAR | +0.02% | -0.02% | |
| BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Verona Pharma plc (Nasdaq - VRNA), Olo Inc. (NYSE - OLO), Guaranty Bancshares, Inc. (NYSE - GNTY), MRC Global Inc. (NYSE - MRC) | Press release | GlobeNewswire | -0.02% | -0.04% | |
| Form 8-K Verona Pharma plc For: Jul 08 | SEC filing · Form 8-K | SEC EDGAR | +0.01% | -0.08% | |
| Form DEFA14A Verona Pharma plc | SEC filing · Form DEFA14A | SEC EDGAR | +0.01% | -0.08% | |
| VRNA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Verona Pharma plc Is Fair to Shareholders | Press release | Business Wire | -0.01% | -0.04% | |
| Opterion Health AG Appoints Industry Leaders Rice Powell and Mark Hahn to Board of Directors | Press release | GlobeNewswire | -0.45% | +1.28% | |
| Ritedose Unveils State-of-the-Art Distribution and Logistics Facility at Ritedose Performance Park | Press release | PR Newswire | -0.43% | +1.54% | |
| Verona Pharma Announces June 2025 Investor Conference Participation | Press release | GlobeNewswire | +0.34% | -0.70% | |
| MAC Lung Disease Market Poised for Growth Across the 7MM During the Forecast Period (2025-2034) Amid Rising Prevalence and New Therapeutic Solutions | DelveInsight | Press release | PR Newswire | +0.34% | -0.70% | |
| Nuance Pharma Announces Ensifentrine Meets Primary Endpoint in Phase 3 ENHANCE-CHINA Trial for COPD | Press release | PR Newswire | -1.09% | +2.10% | |
| Verona Pharma to Present Seven Analyses of the Phase 3 ENHANCE Studies in COPD at ATS 2025 | Press release | GlobeNewswire | -0.80% | -1.21% | |
| Form 10-Q Verona Pharma plc For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -5.10% | -1.30% | |
| Form 8-K Verona Pharma plc For: Apr 29 | SEC filing · Form 8-K | SEC EDGAR | -5.10% | -1.30% | |
| Verona Pharma Reports First Quarter 2025 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -5.10% | -1.30% | |
| Form 8-K Verona Pharma plc For: Apr 24 | SEC filing · Form 8-K | SEC EDGAR | +1.91% | +4.13% | |
| Ritedose Adds Seventh Syntegon Packaging Line to Expand Single Vial Packaging Capabilities, Support Production of new COPD Drug Ohtuvayre | Press release | PR Newswire | +0.37% | -0.07% | |
| Verona Pharma to Report First Quarter 2025 Financial Results and Provide Corporate Update | Press release | GlobeNewswire | +0.45% | +0.72% | |
| Form 8-K Verona Pharma plc For: Mar 25 | SEC filing · Form 8-K | SEC EDGAR | -0.25% | -2.37% | |
| Verona Pharma Announces Amended Strategic Financing with Oaktree and OMERS | Press release | GlobeNewswire | -0.25% | -2.37% | |
| Form ARS Verona Pharma plc For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.75% | +4.91% | |
| Form DEF 14A Verona Pharma plc For: Apr 24 | SEC filing · Form DEF | SEC EDGAR | +0.75% | +4.91% | |
| Form 10-K Verona Pharma plc For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +1.04% | +0.18% | |
| Form 8-K Verona Pharma plc For: Feb 27 | SEC filing · Form 8-K | SEC EDGAR | +1.04% | +0.18% | |
| Form S-8 Verona Pharma plc | SEC filing · Form S-8 | SEC EDGAR | +1.72% | +4.63% | |
| Verona Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | +1.04% | +0.18% | |
| Verona Pharma Announces March 2025 Investor Conference Participation | Press release | GlobeNewswire | -1.84% | -1.41% | |
| Verona Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update | Press release | GlobeNewswire | -0.61% | -0.88% | |
| Global Airway Clearance Devices for Cystic Fibrosis Market to Show Positive Growth at a CAGR of ~5% by 2032 | DelveInsight | Press release | PR Newswire | +0.40% | -1.21% | |
| Nuance Pharma Announces Approval of Ohtuvayre™ (ensifentrine) in Macau SAR, China | Press release | PR Newswire | +0.40% | -1.21% | |
| Orna Therapeutics Appoints Vikas Sinha to its Board of Directors | Press release | PR Newswire | -5.82% | -5.48% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the VRNA section they belong to.
Where else VRNA is measured.
VRNA earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Novartis AG (NVS) | 326 | +0.03% | 51% |
| Theravance Biopharma, Inc. - Ordinary Shares (TBPH) | 326 | +0.10% | 57% |
| Bionano Genomics, Inc. (BNGO) | 321 | -0.94% | 31% |
| Wave Life Sciences, Inc. (WVE) | 321 | -0.14% | 45% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Verona Pharma plc - American Depositary Shares's median reaction calculated?
Every labeled VRNA news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 325 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 39% of VRNA's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does VRNA's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.